Syndax Pharmaceuticals stock has delivered a 15.0% gain over the past year, yet current valuation checks suggest the shares lean expensive on traditional market multiples and only offer a mixed picture on value overall. For anyone tracking biopharma reratings, the key issue is whether that performance still leaves enough room for a return that fairly compensates for the clinical and funding risks ahead.
- Over the last 12 months, Syndax Pharmaceuticals has gained 15.0%, which puts recent shareholders in the black but raises the bar for future returns at today’s price.
- Expectations for future product approvals and revenue growth can support the current valuation, while uncertainty around trial outcomes and ongoing cash needs may limit how much investors are willing to pay upfront.
- On a broad set of valuation checks, Syndax Pharmaceuticals earns a mixed score of 4 out of 6, which points to neither a clear bargain nor an obviously overstretched stock.
The stock’s next move may depend on whether Syndax Pharmaceuticals can grow into the current multiple quickly enough to justify that 1 year gain without asking investors to accept more risk than the price implies.
Compare Syndax Pharmaceuticals' recent rerating with other high quality biotechs that still screen as attractively priced by running through 33 high quality undervalued stocks.
Has Syndax Pharmaceuticals Run Too Far on Sales?
P/S fits Syndax Pharmaceuticals because the business is still loss making and investors are effectively paying today for potential future product revenue.
The stock trades on a P/S of 6.7x. That sits below the broader Biotechs sector on 12.7x and also under the 13.4x peer average, so the market is not attaching a premium multiple to Syndax at the moment. Even with that discount to the group, the company specific fair P/S ratio implied by the model is lower again at 2.9x, which suggests the current price builds in a richer revenue valuation than that framework supports.
This gap between the present 6.7x and the 2.9x fair level indicates the shares screen as expensive on sales, even though Syndax Pharmaceuticals does not look stretched versus the typical biotech peer on raw P/S alone.
On this P/S lens, Syndax Pharmaceuticals stock appears overvalued relative to the revenues implied by the fair multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Syndax Pharmaceuticals Narrative: What Would Justify Today's Price?
Narratives pick up where the Syndax Pharmaceuticals valuation puzzle leaves off by describing what kind of future on growth, profitability and earnings would need to unfold for the share price to end up meaningfully higher or lower than it is today, and they sit on Simply Wall St's Community page. Each scenario links a fair value estimate to a specific mix of potential catalysts and risks, so you can track which storyline seems to be matching real world outcomes over time.
One of the top community narratives on Syndax Pharmaceuticals: 28% undervalued
"Heavy dependence on a few lead assets exposes Syndax to significant clinical, competitive, and regulatory risks that could disrupt future revenue and margin growth..."
Read one of the top narratives on Syndax Pharmaceuticals
Do you think there's more to the story for Syndax Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
On the current numbers, Syndax Pharmaceuticals screens as overvalued on sales, even before layering in the usual biotech execution risks. Market pricing already asks you to pay up for potential future products, while the broader checks only point to a mixed picture on value. The crux for investors is simple: either future commercialisation justifies that richer revenue multiple, or the market decides the clinical and funding risks deserve a lower starting price.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com